International Stroke Conference 2025  /  Risk Factors and Prevention Posters I  /  Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial
Logo

American Heart Association

  23
  0

Final ID: WP318

Cancer and Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Clinical Trial

Abstract Body: Background: Approximately 50% of ischemic strokes in patients with cancer are classified as cryptogenic after standard evaluation. As cancer and its treatments are associated with increased risk for atrial fibrillation (AF), the pathological substrate for AF—atrial cardiopathy—could be the underlying etiology for some of these cancer-related cryptogenic strokes. However, the relationship between cancer and atrial cardiopathy is uncertain.

Methods: We conducted a post-hoc cross-sectional analysis of baseline data collected from patients enrolled into the ARCADIA trial from 2018-2023 at 185 North American sites. Patients had to be age 45 years or older with a clinical diagnosis of cryptogenic ischemic stroke within the past 180 days and without AF of any duration. Enrolled patients consented to screening for atrial cardiopathy, the presence of which was required for randomization. Linear regression models were used to examine associations between a history of cancer and the three log-transformed atrial cardiopathy biomarkers: serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), P-wave terminal force in ECG lead V1 (PTFV1), and left atrial diameter index (LADI) on echocardiogram.

Results: Among 3,745 patients with cryptogenic stroke, 506 (13.5%) had a history of cancer. Patients with, compared to those without, a history of cancer were older (71 versus 65 years) and more often White (88% versus 74%) and non-Hispanic (94% versus 90%). Medical comorbidities were similar between groups. History of cancer was associated with higher median values of NT-proBNP (126 versus 103 pg/mL, p<0.001) and LADI (1.9 versus 1.8 cm/m2, p<0.001) but similar median values of PTFV1 (3000 versus 3025, p=0.08). After adjusting for demographics and tobacco use, no association remained between history of cancer and NT-proBNP (beta-coefficient, -0.09; 95% CI, -0.20 to 0.03), PTFV1 (beta-coefficient, -0.04; 95% CI, -0.10 to 0.02), or LADI (beta-coefficient, 0.01; 95% CI, -0.01 to 0.04).

Conclusions: In a multicenter prospective cohort of patients with cryptogenic stroke, history of cancer was not independently associated with selected biomarkers for atrial cardiopathy. These data suggest that, in the absence of apparent AF, cancer and atrial cardiopathy may not be linked in patients with stroke.
  • Navi, Babak  ( Weill Cornell Medicine , New York , New York , United States )
  • Longstreth, W  ( Harborview Medical Center , Seattle , Washington , United States )
  • Elkind, Mitchell  ( American Heart Association , New York , New York , United States )
  • Zhang, Cenai  ( Weill Cornell Medicine , New York , New York , United States )
  • Tirschwell, David  ( HARBORVIEW MEDICAL CENTER , Seattle , Washington , United States )
  • Kronmal, Richard  ( University of Washington , Seattle , Washington , United States )
  • Elm, Jordan  ( MEDICAL UNIVERSITY SOUTH CAROLINA , Charleston , South Carolina , United States )
  • Broderick, Joseph  ( UNIVERSITY CINCINNATI , Cincinnati , Ohio , United States )
  • Gladstone, David  ( University of Toronto , Toronto , Ontario , Canada )
  • Kamel, Hooman  ( Weill Cornell Medicine , New York , New York , United States )
    • Author Disclosures:
    Babak Navi: DO have relevant financial relationships ; Independent Contractor:MindRhythm, Inc.:Past (completed) | W Longstreth: DO NOT have relevant financial relationships | Mitchell Elkind: DO have relevant financial relationships ; Research Funding (PI or named investigator):Roche:Past (completed) ; Employee:American Heart Association:Active (exists now) ; Speaker:Atria Academy of Science and Medicine:Past (completed) ; Research Funding (PI or named investigator):BMS-Pfizer Alliance for Eliquis:Past (completed) | Cenai Zhang: DO NOT have relevant financial relationships | David Tirschwell: DO have relevant financial relationships ; Consultant:AbbVie:Past (completed) ; Research Funding (PI or named investigator):Abbott:Active (exists now) | Richard Kronmal: DO NOT have relevant financial relationships | Jordan Elm: DO NOT have relevant financial relationships | Joseph Broderick: DO have relevant financial relationships ; Consultant:Roche:Active (exists now) ; Other (please indicate in the box next to the company name):Novo Nordisk - study medication and after-hour call support for ongoing NIH funded trial:Active (exists now) ; Other (please indicate in the box next to the company name):Kroger - Pharmacy Committee:Active (exists now) ; Consultant:Brainsgate:Past (completed) ; Consultant:Basking Bioscience:Active (exists now) ; Researcher:Genentech:Past (completed) | David Gladstone: No Answer | Hooman Kamel: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Financial disclosures for Hooman Kamel: a PI role in the ARCADIA trial, which received in-kind study drug from the BMS-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; a Deputy Editor role for JAMA Neurology; clinical trial steering/executive committee roles for the STROKE-AF (Medtronic), LIBREXIA-AF (Janssen), and LAAOS-4 (Boston Scientific) trials; consulting or endpoint adjudication committee roles for AbbVie, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; and household ownership interests in TETMedical, Spectrum Plastics Group, and Ascential Technologies.:Active (exists now)
Meeting Info:

International Stroke Conference 2025

2025

Los Angeles, CA

Session Info:

Risk Factors and Prevention Posters I

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A Systematic Review and Network Meta-Analysis of Metastatic Castrate-Resistant Prostate Cancer Therapy Cardiotoxicity Given Metastatic Hormone-Sensitive Prostate Cancer Treatment History

Aziz Moez, Swaby Justin, Deng Brett, Hartshorne Taylor, Desai Shubh, Zhang Allan, Xiao Daniel, Sanchez Darren, Imber Jared, Song Jeffrey, Rivas Alexis, Molony Donald, Guhan Maya, Ranganath Shreyas, Jacob Jerril, Ziaolhagh Ali, Ali Abdelrahman, Yusuf Syed, Canfield Steven, Iliescu Cezar, Monlezun Dominique, Higgason Noel, Brunckhorst Oliver, Roland Jerry, Owen Christopher, Iacobucci Alexander Samuel, Galan Jacob

Efficacy of Atrial Shunt Devices in Heart Failure with Preserved Ejection Fraction: A Systematic review and Meta-analysis of randomized trials.

Prata Alonzo, Gioli-pereira Luciana, Katsuyama Eric, Scardini Pedro Gabriel, Coan Ana Carolina, Fukunaga Christian, Fernandes Julia, Falco Neto Wilson, Petri Santos Pinheiro Rafael, Andrade Naieli

More abstracts from these authors:
Risk of Recurrent Ischemic Stroke Among Patients with Cryptogenic Stroke and Left Ventricular Dysfunction Defined by Left Ventricular Fractional Shortening: A Secondary Analysis of the ARCADIA Trial

Sharma Richa, Merkler Alexander, Nahab Fadi, Jillella Dinesh, Zhang Cenai, Elkind Mitchell, Kamel Hooman, Di Tullio Marco, Kronmal Richard, Longstreth W, Tirschwell David

Recurrent Strokes in the ARCADIA Trial

Tirschwell David, Elkind Mitchell, Kamel Hooman, Kronmal Richard, Longstreth W

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.

   Rate this abstract  (Maximum characters: 500)